# US 2019/0054102 A1 · Anthracycline disulfide intermediates, antibody-drug conjugates and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0054102 A1
- Document ID: US20190054102A1
- Status: Published application
- Kind: A1
- Application number: 16/178,328
- Filed: 2018-11-01
- Published: 2019-02-21
- Earliest claimed: 2014-09-12
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: John A. Flygare; Thomas H. Pillow
- Web page: https://patentgrep.com/patent/US20190054102A1

## CPC

- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 47/6809: {Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides antibody-drug conjugates comprising an antibody conjugated to an anthracycline drug moiety via a disulfide linker, anthracycline disulfide intermediates, and methods of using the antibody-drug conjugates.

## Claims

### Claim 1

A linker-drug intermediate of Formula I
Ant-L-(Z)m—X I
wherein Ant is selected from the structure:
where the wavy line indicates the attachment to L;
L is a linker selected from —CH2O—, —CH2N(R)—, —N(R)—, —N(R)(C1-C12 alkylene)-, —N(R)(C2-C8 alkenylene)-, —N(R)(C2-C8 alkynylene)-, —N(R)(CH2CH2O)n—, and the structure:
where the wavy lines indicate the attachments to Ant and Z; and
Z is an optional spacer selected from —CH2C(O)—, —CH2C(O)NR(C1-C12 alkylene)-, and the structure:
where the wavy lines indicate the attachments to L and X;
R is H, C1-C12 alkyl, or C6-C20 aryl;
Z1 is selected from —(C1-C12 alkylene)-, —(C2-C8 alkenylene)-, —(C2-C8 alkynylene)-, —O(C1-C12 alkylene)-, —O(C2-C8 alkenylene)-, —O(C2-C8 alkynylene)-, and (CH2CH2O)n—;
m is 0 or 1;
n is 1 to 6;
X is pyridyl disulfide where pyridyl is optionally substituted with one or more groups selected from NO2, Cl, F, CN and Br; and
alkylene, alkenylene, alkynylene, alkyl, and aryl are optionally substituted with one or more groups selected from F, Cl, Br, N(CH3)2, and OCH3.

### Claim 2 (depends on 1)

The linker-drug intermediate of claim 1 where L is —CH2O—.

### Claim 3 (depends on 1)

The linker-drug intermediate of claim 1 where L is —N(R)— or —N(R)(C1-C12 alkylene)-.

### Claim 4 (depends on 1)

The linker-drug intermediate of claim 1 wherein Z1 is —(C1-C12 alkylene)- or —O(C1-C12 alkylene)-.

### Claim 5 (depends on 1)

The linker-drug intermediate of claim 1 where L is —CH2O—; m is 1; and Z is

### Claim 6 (depends on 5)

The linker-drug intermediate of claim 5 where Z1 is —O(C1-C12 alkylene)-.

### Claim 7 (depends on 5)

The linker-drug intermediate of claim 5 where R is H or C1-C12 alkyl.

### Claim 8 (depends on 1)

The linker-drug intermediate of claim 1 wherein X is:
where the wavy line indicates the attachments to L or Z;
R1 is NO2, Cl, F, CN or Br, and q is 0, 1, or 2.

### Claim 9 (depends on 1)

The linker-drug intermediate of claim 1 selected from Formulas Ia-c:
where R1 is NO2, Cl, F, or Br; and q is 0, 1, or 2.

### Claim 10 (depends on 9)

The linker-drug intermediate of claim 9 wherein R1 is NO2 and n is 1.

### Claim 11 (depends on 1)

The linker-drug intermediate of claim 1 having Formula Id:

### Claim 12 (depends on 1)

The linker-drug intermediate of claim 1 selected from:

### Claim 13 (depends on 1)

The linker-drug intermediate of claim 1 wherein X is:
where the wavy line indicates the attachments to L or Z.

### Claim 14 (depends on 8)

The linker-drug intermediate of claim 8 wherein X is:
where the wavy line indicates the attachments to L or Z.

### Claim 15 (depends on 3)

The linker-drug intermediate of claim 3 wherein L is selected from the group consisting of NHCH2CH2, NHCH2C(CH3)2, and NHCH2CH(CH3); and
m is 0.

### Claim 16 (depends on 15)

The linker-drug intermediate of claim 15 wherein L is selected from racemic NHCH2CH(CH3), the R stereoisomer of NHCH2CH(CH3), the S stereoisomer of NHCH2CH(CH3), and a mixture of the R and S stereoisomers of NHCH2CH(CH3).

### Claim 17 (depends on 5)

The linker-drug intermediate of claim 5 where Z is

### Claim 18 (depends on 17)

The linker-drug intermediate of claim 17 where Z1 is selected from the group consisting of —OCH2CH2—, —OCH2C(CH3)2—, and —OCH2CH(CH3)—.
